Italia Markets close in 7 hrs 51 mins

FibroGen, Inc. (0IL8.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
8,46-0,60 (-6,62%)
Al 04:15PM BST. Mercato aperto.
Schermo intero
Chiusura precedente9,06
Denaro0,00 x N/D
Lettera0,00 x N/D
Min-Max giorno8,46 - 8,67
Intervallo di 52 settimane8,46 - 8,67
Media VolumeN/D
Beta (5 anni mensile)0,79
Rapporto PE (ttm)N/D
EPS (ttm)-2,33
Prossima data utili28 feb 2022 - 04 mar 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    FibroGen Reports First Quarter 2022 Financial Results

    Completed enrollment in ZEPHYRUS-1 Phase 3 study of pamrevlumab in idiopathic pulmonary fibrosis1Q 2022 revenue of $60.8M, growth of 58% vs. 1Q 2021Significant roxadustat volume growth in China in first quarter 2022 offsetting NRDL price reduction SAN FRANCISCO, May 09, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the first quarter 2022 and provided an update on the company’s recent developments. “We continue our progress in advancing pamrevlumab in

  • GlobeNewswire

    FibroGen to Report First Quarter 2022 Financial Results

    SAN FRANCISCO, April 25, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2022 financial results on Monday, May 9 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment community to further detail the company's corporate and financial performance. Conference Call and Audio Webcast Interested parties may access a live audio webcast of the conference call via the FibroGen website at h

  • GlobeNewswire

    FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-1, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis

    - 356 IPF Patients Enrolled - - Topline Data Anticipated Mid-2023 - SAN FRANCISCO, April 20, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced completion of patient enrollment for ZEPHYRUS-1, the first of two Phase 3 clinical studies of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF), a chronic, progressive, and fatal lung disease. “Completing patient enrollment for ZEPHYRUS-1 brings us closer to delivering evidence that pamrevlumab, an inhibitor of connecti